SPY311.36-0.82 -0.26%
DIA263.33+0.16 0.06%
IXIC9,615.81-67.10 -0.69%
News
SNSS
--
0.00%
--
Edited Transcript of SNSS earnings conference call or presentation 7-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 05/14 14:41
Sunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/10 19:48
H.C. Wainwright Reiterates Neutral on Sunesis Pharmaceuticals, Lowers Price Target to $0.5
H.C. Wainwright reiterates Sunesis Pharmaceuticals (NASDAQ:SNSS) with a Neutral and lowers the price target from $1 to $0.5.
Benzinga · 05/08 14:49
Sunesis Pharmaceuticals Reports First Quarter 2020 Financial Results and Recent Highlights
GlobeNewswire · 05/07 21:05
Sunesis Pharmaceuticals Q1 EPS $(0.050) Beats $(0.070) Estimate, Sales $120.000K Miss $190.000K Estimate
Sunesis Pharmaceuticals (NASDAQ:SNSS) reported quarterly losses of $(0.050) per share which beat the analyst consensus estimate of $(0.070) by 28.57 percent. This is a 50 percent increase over losses of $(0.100) per
Benzinga · 05/07 20:55
Sunesis Pharmaceuticals to Host Conference Call on May 7th to Discuss First Quarter 2020 Financial Results and Recent Highlights
GlobeNewswire · 04/30 12:00
Edited Transcript of SNSS earnings conference call or presentation 10-Mar-20 8:30pm GMT
Thomson Reuters StreetEvents · 04/09 17:36
Is Sunesis Pharmaceuticals (SNSS) Stock Outpacing Its Medical Peers This Year?
Zacks · 04/02 16:30
Is Sunesis Pharmaceuticals (SNSS) Outperforming Other Medical Stocks This Year?
Zacks · 03/17 16:30
Earnings Beat: Sunesis Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Simply Wall St. · 03/13 17:56
Benzinga's Top Upgrades, Downgrades For March 11, 2020
Upgrades
Benzinga · 03/11 13:33
H.C. Wainwright Reiterates Neutral on Sunesis Pharmaceuticals, Raises Price Target to $1
H.C. Wainwright analyst Andrew Fein reiterates Sunesis Pharmaceuticals (NASDAQ:SNSS) with a Neutral and raises the price target from $0.5 to $1.
Benzinga · 03/11 12:03
Wells Fargo Downgrades Sunesis Pharmaceuticals to Equal-Weight, Lowers Price Target to $1
Wells Fargo analyst Jim Birchenough downgrades Sunesis Pharmaceuticals (NASDAQ:SNSS) from Overweight to Equal-Weight and lowers the price target from $3 to $1.
Benzinga · 03/11 11:57
Goldman adds Lilly to Conviction List in premarket analyst action
Seeking Alpha - Article · 03/11 11:24
Sunesis Pharmaceuticals EPS beats by $0.02, beats on revenue
seekingalpha · 03/11 01:09
Sunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q4 2019 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 03/10 23:38
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Recent Highlights
GlobeNewswire · 03/10 21:05
Sunesis Pharmaceuticals Q4 EPS $(0.05) Beats $(0.07) Estimate
Sunesis Pharmaceuticals (NASDAQ:SNSS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 68.75 percent increase over losses of $(0.16) per
Benzinga · 03/10 20:10
Sunesis Pharmaceuticals, Inc. to Host Earnings Call
ACCESSWIRE · 03/10 19:30
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off. The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccine news.
Benzinga · 03/08 20:14